Charles A Jr Rowland
CIK 1383292 · VP, Chief Financial Officer · last filed 2026-02-09
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$953.1K
Companies
11
Total Filings
82
Lifetime Open-Market Net
-$7.41M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Generation Bio Co. (GBIO) Delisted | Director | 0 | $5.34 | $0 | $2.03M | 13 | 2026-02-09 |
| VKTX | Director | 33,150 | $28.75 | $953.1K | -$3.13M | 7 | 2026-01-05 |
| Orchard Therapeutics plc (ORTX) Delisted | Director | 0 | $16.70 | $0 | $0 | 5 | 2024-01-24 |
| Nabriva Therapeutics plc (NBRV) Delisted | Director | 15,277 | $1.42 | $21.7K | $67.0K | 9 | 2022-08-03 |
| Blueprint Medicines Corp (BPMC) Delisted | Director | 5,812 | $129.46 | $752.4K | -$3.40M | 10 | 2021-06-04 |
| Viking Therapeutics, Inc. (VKTXW) Delisted | Director | 30,000 | $4.60 | $138.0K | $154.8K | 6 | 2021-01-06 |
| Vitae Pharmaceuticals, Inc (VTAE) Delisted | Director | — | — | — | $0 | 4 | 2016-10-25 |
| DNIB UNWIND, INC. (BIND) Delisted | Director | — | — | — | $0 | 2 | 2016-06-22 |
| IDENIX PHARMACEUTICALS INC (IDIX) Delisted | Director | — | — | — | $0 | 2 | 2014-08-05 |
| VIROPHARMA INC (VPHM) Delisted | VP, Chief Financial Officer | 79,642 | — | — | -$3.13M | 19 | 2014-01-10 |
| ENDO HEALTH SOLUTIONS INC. (ENDP) Delisted | EVP, CFO & Treasurer | 6,699 | $0.29 | $2.0K | $0 | 2 | 2008-02-25 |
Recent Filings · Page 5 of 9
82 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2018-12-27 | Nabriva Therapeutics plc (NBRV) Delisted | Buy (P) | +53,000 | $69.4K | EDGAR |
| 2018-08-02 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-05-31 | Viking Therapeutics, Inc. (VKTXW) Delisted | Buy (P) | +30,000 | $154.8K | EDGAR |
| 2018-05-04 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-01-03 | Viking Therapeutics, Inc. (VKTXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-09-19 | Nabriva Therapeutics plc (NBRV) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-07-05 | Viking Therapeutics, Inc. (VKTXW) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-27 | — | Other (J) | — | $0 | |
| 2017-06-23 | Blueprint Medicines Corp (BPMC) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.